Atracurium besylate 10mg/mL; soln for IV inj. <1month: not recommended. Individualize. 1month to 2yrs (under halothane anesthesia): initially 0.3–0.4mg/kg. ≥2yrs: initially 0.4–0.5mg/kg IV bolus.

Review the side-effects of Atracurium as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

NEW DELHI: Drug major Aurobindo Pharma has received final approval from the US health regulator to manufacture and market Atracurium Besylate injections in the American market. "The company has ...

Sagent Pharmaceuticals ($SGNT) has transferred production of atracurium besylate injection to its own plant after the FDA spotted GMP problems at the CMO that was ...

Learn everything you need to know about Atracurium-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

The company voluntarily recalls product due to FDA observations of potential sterility problems. FDA announced on Feb. 23, 2015 that Sagent Pharmaceuticals has issued a voluntary recall of two lots of ...

Sagent Pharmaceuticals announced the launch of Atracurium Besylate Injection, the generic form of the neuromuscular blocker Tracrium, in 50 mg per 5mL latex-free vials. Atracurium Besylate Injection ...

Aurobindo Pharma Ltd has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Atracurium Besylate Injection, 10mg/mL, 5mL single-dose vials and 10mg/mL, ...

At present, the company has 11 ANDAs approved out of its Unit IV formulation facility in Hyderabad, manufacturing general injectable products, Aurbindo Pharma added. Aurobindo Pharma shares were ...